NasdaqGS - Delayed Quote • USD
Adaptimmune Therapeutics plc (ADAP)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 6:58 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | -0.11 | -0.15 | -0.56 | -0.53 |
| Low Estimate | -0.2 | -0.21 | -0.77 | -0.8 |
| High Estimate | -0.04 | -0.03 | -0.14 | -0.24 |
| Year Ago EPS | -0.12 | -0.2 | -0.54 | -0.56 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 8 | 8 | 8 |
| Avg. Estimate | 33.98M | 9.5M | 58.77M | 44.82M |
| Low Estimate | 4M | 500k | 23.7M | 12.04M |
| High Estimate | 84.9M | 25M | 99.46M | 105.5M |
| Year Ago Sales | 5.13M | 7.32M | 60.28M | 58.77M |
| Sales Growth (year/est) | 562.40% | 29.80% | -2.50% | -23.70% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.13 | -0.12 | -0.1 | -0.1 |
| EPS Actual | -0.12 | -0.2 | -0.24 | -0.18 |
| Difference | 0.01 | -0.08 | -0.14 | -0.08 |
| Surprise % | 7.70% | -66.70% | -140.00% | -80.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.11 | -0.15 | -0.56 | -0.53 |
| 7 Days Ago | -0.11 | -0.15 | -0.56 | -0.48 |
| 30 Days Ago | -0.06 | -0.08 | -0.28 | -0.42 |
| 60 Days Ago | -0.06 | -0.08 | -0.27 | -0.37 |
| 90 Days Ago | -0.08 | -0.11 | -0.37 | -0.39 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 2 |
| Up Last 30 Days | 1 | 1 | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ADAP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 8.30% | -- | -- | 9.10% |
| Next Qtr. | 25.00% | -- | -- | 11.50% |
| Current Year | -3.70% | -- | -- | 5.70% |
| Next Year | 5.40% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 1.00% | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Scotiabank: Sector Outperform | 5/30/2024 |
| Maintains | Mizuho: Buy to Buy | 5/17/2024 |
| Maintains | Barclays: Underweight to Underweight | 8/10/2023 |
| Reiterates | EF Hutton: Buy to Buy | 8/10/2023 |
| Reiterates | EF Hutton: Buy to Buy | 6/5/2023 |
| Reiterates | EF Hutton: Buy | 6/2/2023 |
Related Tickers
AFMD Affimed N.V.
6.14
-2.69%
FGEN FibroGen, Inc.
1.1000
-7.56%
GLPG Galapagos NV
26.76
-1.07%
IOVA Iovance Biotherapeutics, Inc.
7.78
-4.42%
VNDA Vanda Pharmaceuticals Inc.
6.12
-2.39%
ALGS Aligos Therapeutics, Inc.
0.5401
-6.56%
ABEO Abeona Therapeutics Inc.
4.2700
-0.23%
IMCR Immunocore Holdings plc
41.68
-2.37%
FRES Fresh2 Group Limited
0.4375
-5.91%
MREO Mereo BioPharma Group plc
3.4200
-0.58%